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Abstract
Objective: Total bilirubin (TB) of >7 mg/dl is an accepted definition of postoperative hepatic insufficiency
(PHI) given its association with the occurrence of complications and mortality after hepatectomy. The aim
of this study was to identify a surrogate marker for PHI early in the postoperative course.
Methods: A single-institution database of patients undergoing major hepatectomy (three or more
segments) during 2000–2012 was retrospectively reviewed. Demographic, clinicopathologic and
perioperative factors were assessed for their association with PHI, defined as postoperative TB of
>7 mg/dl or new ascites. Secondary outcomes included complications, major complications (Clavien–
Dindo Grades III–V) and 90-day mortality.
Results: A total of 607 patients undergoing major hepatectomy without bile duct reconstruction were
identified. Postoperative hepatic insufficiency occurred in 60 (9.9%) patients. A postoperative day 3
(PoD 3) TB level of ≥3 mg/dl was the only early perioperative factor associated with the development of
PHI on multivariate analysis [hazard ratio (HR) = 7.81, 95% confidence interval (CI) 3.74–16.31; P < 0.001].
A PoD 3 TB of ≥3 mg/dl was associated with increased risk for postoperative complications (75.7%
versus 53.9%), major complications (45.6% versus 17.6%), and 90-day mortality (15.5% versus 2.3%).
This association persisted on multivariate analysis for any complications (HR = 1.98, 95% CI 1.10–3.54;
P = 0.022), major complications (HR = 3.18, 95% CI 1.90–5.32; P < 0.001), and 90-day mortality (HR =
8.11, 95% CI 3.00–21.92; P < 0.001).
Conclusions: Total bilirubin of ≥3 mg/dl on PoD 3 after major hepatectomy is associated with PHI,
increased complications, major complications and 90-day mortality. This marker may serve as an early
postoperative predictor of hepatic insufficiency.
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Introduction
Improvements in patient selection, perioperative management,
cross-sectional imaging and surgical techniques in liver resection
have led to increases in both the indications for hepatectomy and
the number of operations performed. Once as high as 20%, mor-
tality rates after major hepatectomy have recently been reported
to be as low as 1.3%.1–5Although it is not a frequent occurrence,
postoperative hepatic insufficiency (PHI) is a devastating
complication that remains a major cause of post-hepatectomy
mortality.3,6,7
In the last decade, in excess of 50 studies have sought to define
post-hepatectomy liver failure.2,8–11 Many authors incorporate
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postoperative serum bilirubin values and the international nor-
malized ratio (INR) in their definitions; others consider clinical
conditions, such as hepatic encephalopathy or ascites, and still
others use a combination of the two.2,12,13 The timing of the meas-
urement of these variables in the postoperative period is also
inconsistent: some studies measure at 4, 5 and 7 days postopera-
tively, whereas others describe merely the presence of a particular
variable at any time-point. For example, the ‘50–50 criteria’ utilize
both bilirubin level and INR on postoperative day 5 (PoD 5) as
predictors of post-hepatectomy mortality. By contrast, Hyder
et al. proposed a comprehensive algorithm for predicting PHI
after hepatectomy.4 One of the most commonly accepted and
simplest definitions of PHI is a peak total serum bilirubin of
>7 mg/dl in the postoperative period.2 Regardless of which defi-
nition of PHI is applied, all of them are limited by the fact that
in most patients PHI is not identified until late in the postopera-
tive course. An early predictor of PHI and adverse outcomes
would be helpful to identify at-risk patients. The aim of this
study was to identify a simple and early postoperative predictor
of subsequent hepatic insufficiency and other adverse out-
comes, including complications and early mortality, after major
hepatectomy.
Materials and methods
Institutional review board approval for this study was obtained
and the protocol was conducted in accordance with the Health
Insurance Portability and Accountability Act of 1996. All patients
who underwent major hepatectomy, defined as the resection of
three or more anatomical liver segments, between January 2000
and July 2012 were identified from a prospectively maintained,
single-institution database. Patients who underwent biliary recon-
struction and those for whom bilirubin data were inadequate were
excluded from this study.
A complete review of medical records was performed. Basic
demographic and clinicopathologic data were collected and rec-
orded in the database, as were preoperative and postoperative
relevant laboratory values, operative details and outcomes. Indi-
vidual total bilirubin levels and INR were recorded on PoDs 1–5.
When multiple values were available for a single 24-h period, the
highest value was recorded as the value for that time period. Peak
postoperative total bilirubin and INR for up to 30 days postop-
eratively were recorded.
The study objective was to identify a predictor of PHI early
in the postoperative period. The primary outcome was PHI,
specifically defined as a peak postoperative bilirubin level of
>7 mg/dl and/or the presence of new ascites.2,14 Secondary out-
comes included any complication, major complications defined
as those of Clavien–Dindo Grades III–V, and 90-day all-cause
mortality.15
All demographic, clinicopathologic and operative data were
assessed for significant relationships with PHI using the chi-
squared or Fisher’s exact tests for categorical variables and
Student’s t-test or the Mann–Whitney U-test for continuous vari-
ables, as appropriate. Variables associated with PHI were identified
on univariate analysis; those found to have a statistically signifi-
cant association (P < 0.05) were included in a multivariate logistic
regression to assess independent correlation. Receiver operating
characteristic (ROC) curve analysis was performed to identify the
total bilirubin level in the early postoperative period that was best
associated with the subsequent development of PHI. Once this
value was identified, univariate and multivariate models were con-
structed for each secondary endpoint. Finally, demographic and
pre- and intraoperative clinicopathologic variables were analysed
for their associations with the early postoperative bilirubin level
that best predicted PHI. A P-value of < 0.05 was considered to
indicate statistical significance.
Results
Of the 751 patients who underwent major hepatectomy at Emory
University Hospital during 2000–2012, 144 (19.2%) patients
underwent concomitant biliary reconstruction and were conse-
quently excluded from this study. Of the remaining 607 patients,
535 (88.1%) had sufficient data on total bilirubin levels available
for analysis. Demographic, clinicopathologic and perioperative
data are summarized in Table 1. The cohort included 443 patients
(73.0%) with a diagnosis of cancer, of which the most common
indication for operation was colorectal liver metastasis (n = 232,
52.4%). The mean ± standard deviation (SD) preoperative total
bilirubin level was 0.7 ± 0.65 mg/dl.
Sixty patients (11.2%) met the criteria for PHI. Postoperative
complications occurred in 352 patients (65.8%) and major
complications (Clavien–Dindo Grades III–V) occurred in 125
(23.4%). The 90-day mortality rate was 5.0% (n = 27) and the
readmission rate was 17.4% (n = 93).
To identify an early postoperative indicator of PHI, an ROC
curve was constructed (Fig. 1) to ascertain the early postoperative
bilirubin level best associated with PHI. Bilirubin levels for the
first 3 days postoperatively were analysed and that for PoD 3
revealed the best fit curve [area under the curve (AUC): 0.85].
A PoD 3 bilirubin value of ≥3 mg/dl had the strongest associa-
tion with the subsequent development of PHI, with sensitivity
of 60% and specificity of 86%. The positive predictive value of
PoD 3 bilirubin of ≥3 mg/dl for the development of PHI was
33.0% (34 of 103 patients), and the negative predictive value was
94.0% (406 of 432 patients).
On univariate analysis, several demographic and preopera-
tive variables were found to be significantly associated with
PHI, including older age, male gender, cancer diagnosis, low
preoperative albumin, a preoperative Model for End-stage Liver
Disease (MELD) score of ≥8, and a preoperative tissue diagnosis
of cirrhosis. Perioperative variables that significantly increased
the risk for progression to PHI were higher intraoperative esti-
mated blood loss (EBL), requirement for intraoperative blood
transfusion, fresh frozen plasma (FFP) transfusion before PoD 2,
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and a PoD 3 total bilirubin level of ≥3 mg/dl. Of all of these
factors, only PoD 3 total bilirubin of ≥3 mg/dl demonstrated
an independent association with PHI on multivariate analysis
(Table 2).
On PoD 3, 432 patients showed a total bilirubin level of
< 3 mg/dl and 103 showed a total bilirubin level of ≥3 mg/dl.
Patients with a PoD 3 total bilirubin level of ≥3 mg/dl demon-
strated a significantly increased risk for the occurrence of
any complication (75.7% versus 53.9%; P < 0.001), a major
Table 1 Demographic, clinicopathologic and perioperative variables
in all patients (n = 607)
Clinicopathologic variable Value
Age, years, median (range) 56.5 (19.0–87.8)
Male gender, n (%) 253 (41.7%)
Race, n (%)
White 406 (66.9%)
Black 131 (21.6%)
Other 50 (8.2%)
BMI, kg/m2, median (range) 26.7 (16.6–45.9)
Smoking history, n (%) 176 (29.0%)
Diabetes mellitus, n (%) 106 (17.5%)
Cancer, n (%) 443 (73.0%)
Preoperative chemotherapy, n (%) 234 (38.6%)
Prior hepatectomy, n (%) 22 (3.8%)
Pathology, n (%)
Colorectal metastases 232 (38.2%)
Benign 177 (29.2%)
Hepatocellular carcinoma 68 (11.2%)
Other metastatic disease 62 (10.2%)
Cholangiocarcinoma 36 (5.9%)
Metastatic neuroendocrine 32 (5.3%)
Other primary malignancy 1 (0.2%)
Preoperative platelet count, ×103/ml, median
(range)
233 (68–903)
Preoperative INR 1.00 (0.81–2.61)
Preoperative total bilirubin, mg/dl, median (range) 0.6 (0.1–9.3)
MELD score, mean ± SD 7.6 ± 2.8
Preoperative PVE, n (%) 23 (3.8%)
Cirrhosis (on pathology), n (%) 18 (3%)
Operation technique, n (%)
Laparoscopic 83 (13.7%)
Open 505 (83.2%)
Converted 19 (3.1%)
Intraoperative ablation, n (%) 57 (9.4%)
EBL, ml, mean (range) 350 (50–5900)
Operation type, n (%)
Central hepatectomy 18 (3%)
Extended left 37 (6%)
Extended right 94 (15%)
Formal left 112 (18%)
Formal right 267 (44%)
Non-anatomic 79 (13%)
Pringle manoeuvre 329 (64%)
Postoperative FFP requirement 129 (21.2%)
PoD 3 total bilirubin, mg/dl, median (range) 1.5 (0.3–10.6)
PoD 3 total bilirubin of ≥3 mg/dl, n (%) 103 (19.3%)
BMI, body mass index; INR, international normalized ratio; MELD, Model
for End-stage Liver Disease; SD, standard deviation; PVE, portal vein
embolization; EBL, estimated blood loss; FFP, fresh frozen plasma;
PoD 3, postoperative day 3.
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Figure 1 Receiver operating characteristic curve for bilirubin levels
on postoperative day 3 as a marker for postoperative hepatic insuf-
ficiency (bilirubin of 3 mg/dl denoted by arrow). Area under the
curve: 0.850
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Figure 2 Postoperative outcomes after major hepatectomy, strati-
fied by postoperative day 3 (PoD 3) serum total bilirubin (TB) level.
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HPB 877
HPB 2014, 16, 875–883 © 2014 International Hepato-Pancreato-Biliary Association
complication (45.6% versus 17.6%; P < 0.001), and 90-day mor-
tality (15.5% versus 2.3%; P < 0.001) (Fig. 2).
Univariate and multivariate logistic regression models were
developed for each secondary outcome of any complication,
major complications and 90-day mortality (Tables 3–5). Risk
factors for any complication include American Society of
Anesthesiologists (ASA) class ≥3 status, an FFP transfusion
requirement on or before PoD 2, and PoD 3 total bilirubin of
≥3 mg/dl. Risk factors for the occurrence of a major complica-
tion include White European ethnicity, an FFP transfusion
requirement on or before PoD 2, and PoD 3 total bilirubin of
≥3 mg/dl. Variables associated with increased risk for 90-day
mortality include older age and PoD 3 total bilirubin of ≥3 mg/
dl. Importantly, only PoD 3 total bilirubin of ≥3 mg/dl was
significantly associated on multivariate analysis with all three
outcomes of any complication, a major complication and 90-day
mortality.
Pre- and intraoperative factors were evaluated for their asso-
ciation with the development of a PoD 3 total bilirubin level of
≥3 mg/dl. Patients with PoD 3 bilirubin of ≥3 mg/dl were more
likely to be male (57.3%; P = 0.001), have cancer (85.4%; P =
0.003), have a preoperative platelet count of < 150 000 (16.5%;
P = 0.013), have a preoperative MELD score of ≥8 (33.7%; P =
0.007), have higher EBL (P = 0.008), and receive intraoperative
blood transfusions (32.4%; P = 0.019). However, in a multi-
variate analysis model, none of the pre- or intraoperative factors
emerged as predictive of a PoD 3 total bilirubin level of ≥3 mg/dl
(Table 6).
Table 2 Univariate and multivariate analysis of risk factors for postoperative hepatic insufficiency (PHI) following major hepatectomy in
607 patients
Univariate analysis Multivariate analysis
PHI
(n = 60)
No PHI
(n = 547)
P-value HR 95% CI P-value
Age, years, mean ± SD 58.5 ± 14.1 54.8 ± 13.8 0.048 1.02 0.99–1.04 0.166
Male gender, n (%) 36 (60.0%) 217 (39.7%) 0.004 1.11 0.55–2.25 0.767
Race (White), n (%) 42 (70.0%) 364 (66.5%) 0.693
BMI, kg/m2, mean ± SD 26.9 ± 5.8 27.6 ± 5.9 0.378
Smoking, n (%) 20 (33.3%) 156 (28.5%) 0.528
Diabetes, n (%) 11 (18.3%) 95 (17.4%) 0.994
Cancer, n (%) 52 (86.7%) 391 (71.5%) 0.018 1.90 0.70–5.18 0.208
Preoperative chemotherapy, n (%) 28 (46.7%) 206 (38.0%) 0.244
Prior hepatectomy, n (%) 3 (5.0%) 19 (3.5%) 0.813
Preoperative platelet count ≥150 × 103/ml 50 (84.7%) 500 (91.6%) 0.135
Portal vein embolization, n (%) 5 (8.3%) 18 (3.3%) 0.115
Preoperative albumin ≥3.0 g/dl, n (%) 47 (78.3%) 488 (89.4%) 0.021 0.63 0.26–1.55 0.312
MELD score ≥8, n (%) 24 (40.0%) 110 (20.1%) 0.001 1.66 0.79–3.47 0.180
Cirrhosis (on pathology), n (%) 6 (10.0%) 12 (2.2%) 0.003 2.64 0.75–9.30 0.132
Length of operation, min, mean ± SD 207 ± 74 214 ± 91 0.633
Pringle manoeuvre, n (%) 39 (76.5%) 297 (63.2%) 0.084
Extended hepatectomy, n (%) 17 (28.3%) 114 (20.8%) 0.240
ASA class ≥3, n (%) 40 (69.0%) 357 (65.7%) 0.729
ECOG grade ≥1, n (%) 26 (46.4%) 182 (38.0%) 0.280
Laparoscopic, n (%) 3 (5.0%) 80 (14.6%) 0.063
Intraoperative ablation, n (%) 3 (5.0%) 54 (9.9%) 0.348
EBL, ml, mean ± SD 1034 ± 1440 549 ± 615 0.013 1.00 1.00–1.00 0.063
Intraoperative RBC transfusion, n (%) 23 (39.0%) 123 (22.5%) 0.008 1.32 0.56–3.12 0.533
FFP PoD 0-2, n (%) 20 (33.3%) 86 (15.7%) 0.001 0.71 0.29–1.69 0.432
PoD 3 TB ≥3 mg/dl, n (%) 34 (60.7%) 69 (14.4%) <0.001 7.78 4.05–14.94 <0.001
HR, hazard ratio; 95% CI, 95% confidence interval; SD, standard deviation; BMI, body mass index; MELD, Model for End-stage Liver Disease;
ASA, American Society of Anesthesiologists; ECOG, Eastern Cooperative Oncology Group; EBL, estimated blood loss; RBC, red blood cells;
FFP, fresh frozen plasma; PoD, postoperative day.
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Discussion
The purpose of this study was to identify an early predictor of
PHI. When PHI was defined as total serum bilirubin of >7 mg/dl
and/or the formation of new ascites, PoD 3 bilirubin was predic-
tive of subsequent PHI. Specifically, a PoD 3 bilirubin level of
≥3 mg/dl was associated with increased risk for PHI [hazard ratio
(HR) = 7.78, 95% confidence interval (CI) 4.05–14.94; P < 0.001],
as well as for postoperative complications (HR = 1.98, 95% CI
1.10–3.54; P = 0.022), major postoperative complications (HR =
3.18, 95% CI 1.90–5.32; P < 0.001) and 90-day mortality (HR =
8.11, 95% CI 3.00–21.92; P < 0.001).
Analysis of the ROC curve revealed that PoD 3 bilirubin
rendered the best fit curve for PHI, with an AUC of 0.85. The
dichotomizing of patients according to bilirubin levels of <
3 mg/dl and ≥3 mg/dl provided sensitivity of 60% and specifi-
city of 86%. When tested in a multivariate model with other
factors associated with PHI, a PoD 3 bilirubin level of ≥3 mg/dl
remained the only factor significantly associated with PHI
(Tables 2–5).
The consistency of PoD 3 total bilirubin of ≥3 mg/dl as
an early predictor of PHI was internally validated by determin-
ing its association with the secondary outcomes of any com-
plication, a major complication and 90-day mortality. On
multivariate regression analysis, a PoD 3 total bilirubin level
of ≥3 mg/dl was the only perioperative factor to remain
significantly associated with all three secondary outcomes
(Tables 3–5).
Table 3 Univariate and multivariate analysis of risk factors for any postoperative complication following major hepatectomy in
607 patients
Univariate analysis Multivariate analysis
Postoperative
complication
(n = 352)
No postoperative
complication
(n = 255)
P-value HR 95% CI P-value
Age, years, mean ± SD 56.4 ± 13.9 53.3 ± 13.5 0.006 1.01 0.99–1.03 0.276
Male gender, n (%) 94 (36.9%) 159 (45.2%) 0.049 1.39 0.88–2.22 0.162
Race (White), n (%) 239 (67.9%) 167 (65.5%) 0.593
BMI, kg/m2, mean ± SD 27.5 ± 5.9 27.6 ± 6.0 0.912
Smoking, n (%) 113 (32.1%) 63 (24.7%) 0.059
Diabetes, n (%) 69 (19.6%) 37 (14.5%) 0.128
Cancer, n (%) 272 (77.3%) 171 (67.1%) 0.007 0.90 0.52–1.55 0.700
Preoperative chemotherapy, n (%) 138 (39.7%) 96 (37.8%) 0.706
Prior hepatectomy, n (%) 16 (4.5%) 6 (2.4%) 0.228
Preoperative platelet count ≥150 × 103/ml, n (%) 316 (90.0%) 234 (92.1%) 0.458
Portal vein embolization, n (%) 17 (4.9%) 6 (2.4%) 0.172
Preoperative albumin ≥3.0 g/dl, n (%) 299 (84.9%) 236 (92.9%) 0.004 0.55 0.27–1.14 0.108
MELD score ≥8, n (%) 94 (26.7%) 40 (15.7%) 0.002 1.10 0.67–2.11 0.555
Cirrhosis (on pathology), n (%) 14 (4.0%) 4 (1.6%) 0.094
Length of operation, min, mean ± SD 219 ± 101 208 ± 76 0.209
Pringle manoeuvre, n (%) 205 (68.6%) 131 (59.0%) 0.031 1.001 0.61–1.66 0.997
Extended hepatectomy, n (%) 80 (22.7%) 51 (20.0%) 0.480
ASA class ≥3, n (%) 254 (73.0%) 143 (56.5%) <0.001 1.87 1.15–3.03 0.011
ECOG Grade 1, n (%) 128 (41.2%) 80 (35.7%) 0.236
Laparoscopic, n (%) 28 (8.0%) 55 (21.6%) <0.001 0.52 0.26–1.03 0.062
Introspective ablation, n (%) 34 (9.7%) 23 (9.0%) 0.900
EBL, ml, mean ± SD 735 ± 854 404 ± 518 <0.001
Intraoperative RBC transfusion, n (%) 112 (31.9%) 34 (13.3%) <0.001 1.02 0.51–2.03 0.959
FFP PoD 0-2, n (%) 97 (27.6%) 9 (3.5%) <0.001 7.69 3.16–18.71 <0.001
PoD 3 TB ≥3 mg/dl, n (%) 78 (25.1%) 25 (11.2%) <0.001 1.98 1.10–3.54 0.022
HR, hazard ratio; 95% CI, 95% confidence interval; SD, standard deviation; BMI, body mass index; MELD, Model for End-stage Liver Disease;
ASA, American Society of Anesthesiologists; ECOG, Eastern Cooperative Oncology Group; EBL, estimated blood loss; RBC, red blood cells;
FFP, fresh frozen plasma; PoD, postoperative day.
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In an effort to identify at-risk patients even earlier in their
treatment course, pre- and intraoperative factors were assessed
for their associations with a PoD 3 total bilirubin level of ≥3 mg/
dl. Although several variables were associated with PoD 3 total
bilirubin of ≥3 mg/dl, none of these associations persisted on
multivariate analysis. Thus, although PoD 3 total bilirubin of
≥3 mg/dl is an early postoperative predictor that confers signifi-
cant risk for morbidity and mortality, there were no pre- or
intraoperative risk factors that allowed for the earlier identifica-
tion of these patients.
The indications and selection criteria for performing major
hepatectomy are continuing to expand.3,6,16,17 Even with existing
techniques, such as volumetric measurements and portal vein
embolization to optimize the future liver remnant, PHI remains
a significant concern because it is associated with increased
morbidity and mortality. Although numerous studies have
attempted to produce a standard definition for PHI, there is no
universally accepted classification. Furthermore, many of these
current definitions are subject to retrospective analysis or late-
course recognition. A PoD 3 bilirubin level of ≥3 mg/dl identifies
patients who are at significant risk for complications and 90-day
mortality, as well as possibly serving as an early indicator of PHI.
There are several limitations to this study. One major limitation
concerns the current lack of clinical treatment alternatives in the
context of the early identification of risk for PHI. It is possible that
as bridging treatments such as molecular adsorbent recirculating
Table 4 Univariate and multivariate analysis of risk factors for major postoperative complication following major hepatectomy in
607 patients
Univariate analysis Multivariate analysis
Major
complication
(n = 135)
No major
complication
(n = 472)
P-value HR 95% CI P-value
Age, years, mean ± SD 57.6 ± 14.1 54.4 ± 13.7 0.019 1.01 0.99–1.03 0.480
Male gender, n (%) 72 (52.9%) 181 (38.4%) 0.003 1.26 0.78–2.06 0.367
Race (White), n (%) 103 (75.7%) 303 (64.3%) 0.017 1.88 1.13–3.10 0.014
BMI, kg/m2, mean ± SD 27.3 ± 5.5 27.6 ± 6.0 0.638
Smoking, n (%) 46 (33.8%) 130 (27.6%) 0.193
Diabetes, n (%) 27 (19.9%) 79 (16.8%) 0.481
Cancer, n (%) 112 (82.4%) 331 (70.3%) 0.007 1.18 0.64–2.19 0.599
Preoperative chemotherapy, n (%) 55 (40.4%) 179 (38.4%) 0.744
Prior hepatectomy, n (%) 5 (3.7%) 17 (3.6%) 1.000
Preoperative platelet count ≥150 × 103/ml, n (%) 117 (86.7%) 433 (92.1%) 0.076
Portal vein embolization, n (%) 6 (4.4%) 17 (3.6%) 0.870
Preoperative albumin ≥3.0 g/dl, n (%) 109 (80.1%) 426 (90.6%) 0.001 0.55 0.29–1.04 0.067
MELD score ≥8, n (%) 48 (35.3%) 86 (18.3%) <0.001 1.67 0.97–2.86 0.064
Cirrhosis, n (%) 7 (5.1%) 11 (2.3%) 0.157
Length of operation, min, mean ± SD 222 ± 103 212 ± 86 0.374
Pringle manoeuvre, n (%) 81 (66.4%) 255 (63.9%) 0.694
Extended hepatectomy, n (%) 33 (24.3%) 98 (20.8%) 0.456
ASA class ≥3, n (%) 102 (76.1%) 295 (63.2%) 0.007 1.45 0.83–2.53 0.194
ECOG grade ≥1, n (%) 56 (48.7%) 152 (36.2%) 0.048 1.23 0.84–1.79 0.284
Laparoscopic, n (%) 13 (9.6%) 70 (14.9%) 0.149
Intraoperative ablation, n (%) 13 (9.6%) 44 (9.3%) 1.000
EBL, ml, mean ± SD 832 ± 1040 528 ± 627 0.002 1.00 1.00–1.00 0.604
Intraoperative RBC transfusion, n (%) 46 (34.1%) 100 (21.2%) 0.003 0.95 0.49–1.84 0.881
FFP PoD 0-2, n (%) 47 (34.6%) 59 (12.5%) <0.001 2.49 1.35–4.59 0.004
PoD 3 TB ≥3 mg/dl, n (%) 47 (38.2%) 56 (13.6%) <0.001 3.18 1.90–5.32 <0.001
HR, hazard ratio; 95% CI, 95% confidence interval; SD, standard deviation; BMI, body mass index; MELD, Model for End-stage Liver Disease;
ASA, American Society of Anesthesiologists; ECOG, Eastern Cooperative Oncology Group; EBL, estimated blood loss; RBC, red blood cells;
FFP, fresh frozen plasma; PoD, postoperative day.
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systems and plasma separation and filtration are developed for the
injured liver, the early identification of these patients may become
more clinically relevant and time-sensitive because a therapeutic
option to improve liver function or support the body while the
liver recuperates can be provided.18–20 Other limitations include
the retrospective method of analysis, which limits the interpreta-
tion of causality between predictors and outcomes and suggests
only association. An additional limitation of the present study
refers to the lack of standardized, specific clinical management
protocols, such as for blood product transfusion, which were
based on physician-specific clinical decision making. Finally, the
future liver remnant, although an important consideration in
patients with PHI, is not routinely calculated and thus could not
be included in the analysis.
In this series of 535 patients submitted to major hepatectomy,
a total bilirubin level of ≥3 mg/dl on PoD 3 was associated with
the development of PHI, and increased risk for any postoperative
complications, major postoperative complications and 90-day
mortality. No preoperative risk factors correctly identified pati-
ents at risk for developing a total bilirubin level of ≥3 mg/dl on
PoD 3. Although a PoD 3 total bilirubin level of ≥3 mg/dl may be
an early-course predictor of PHI, continued research is necessary
to identify preoperative predictors of and rescue treatments for
PHI.
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Table 5 Univariate and multivariate analysis of risk factors for 90-day mortality following major hepatectomy in 607 patients
Univariate analysis Multivariate analysis
90-day
mortality
(n = 27)
No 90-day
mortality
(n = 580)
P-value HR 95% CI P-value
Age, years, mean ± SD 66.6 ± 9.1 54.6 ± 13.8 <0.001 1.09 1.04–1.15 <0.001
Male gender, n (%) 16 (59.3%) 237 (40.9%) 0.090
Race (White), n (%) 18 (66.7%) 388 (66.9%) 1.000
BMI, kg/m2, mean ± SD 27.2 ± 4.5 27.6 ± 6.0 0.768
Smoking, n (%) 9 (33.3%) 167 (28.8%) 0.771
Diabetes, n (%) 10 (37.0%) 96 (16.6%) 0.013 1.75 0.60–5.15 0.305
Cancer, n (%) 26 (96.3%) 417 (71.9%) 0.010 6.55 0.54–79.29 0.140
Preoperative chemotherapy, n (%) 10 (37.0%) 224 (39.0%) 1.000
Prior hepatectomy, n (%) 3 (11.1%) 19 (3.3%) 0.069
Preoperative platelet count ≥150 × 103/ml, n (%) 21 (77.8%) 529 (91.5%) 0.037 0.47 0.15–1.50 0.201
Portal vein embolization, n (%) 2 (7.4%) 21 (3.6%) 0.275
Preoperative albumin ≥3.0 g/dl, n (%) 19 (70.4%) 516 (89.1%) 0.008 0.45 0.13–1.57 0.212
MELD score ≥8, n (%) 13 (48.1%) 121 (20.9%) 0.002 1.23 0.46–3.33 0.682
Cirrhosis (on pathology), n (%) 4 (14.8%) 14 (2.4%) 0.006 2.89 0.63–13.30 0.172
Length of operation, min, mean ± SD 196 ± 79 214 ± 90 0.454
Pringle manoeuvre, n (%) 15 (62.5%) 321 (64.6%) 1.000
Extended hepatectomy, n (%) 7 (25.9%) 124 (21.4%) 0.747
ASA class ≥3, n (%) 22 (81.5%) 375 (65.3%) 0.127
ECOG grade ≥1, n (%) 17 (65.4%) 191 (37.5%) 0.008 1.40 0.69–2.86 0.354
Laparoscopic, n (%) 2 (7.4%) 81 (14.0%) 0.564
Intraoperative ablation, n (%) 2 (7.4%) 55 (9.5%) 1.000
EBL, ml, mean ± SD 1178 ± 1389 569 ± 696 <0.001 1.00 1.000–1.001 0.307
Intraoperative RBC transfusion, n (%) 14 (51.9%) 132 (22.8%) 0.001 1.37 0.39–4.77 0.626
FFP PoD 0-2, n (%) 13 (48.1%) 93 (16.0%) <0.001 1.17 0.37–3.72 0.791
PoD 3 TB ≥3 mg/dl, n (%) 16 (61.5%) 87 (17.1%) <0.001 8.11 3.00–21.92 <0.001
HR, hazard ratio; 95% CI, 95% confidence interval; SD, standard deviation; BMI, body mass index; MELD, Model for End-stage Liver Disease;
ASA, American Society of Anesthesiologists; ECOG, Eastern Cooperative Oncology Group; EBL, estimated blood loss; RBC, red blood cells;
FFP, fresh frozen plasma; PoD, postoperative day.
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